Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 Dec;39(12):2661–2666. doi: 10.1128/aac.39.12.2661

Monitoring of co-trimoxazole concentrations in serum during treatment of pneumocystis carinii pneumonia.

B Joos 1, J Blaser 1, M Opravil 1, J P Chave 1, R Lüthy 1
PMCID: PMC163008  PMID: 8592998

Abstract

The purpose of this prospective randomized open trial was to investigate the impact of monitoring concentrations in serum on the efficacy and side effects of high-dose co-trimoxazole therapy. Forty consecutive patients with microscopically confirmed Pneumocystis carinii pneumonia were enrolled. Therapy was started with 5 and 25 mg of trimethoprim and sulfamethoxazole, respectively, per kg of body weight given every 6 h for 2 days and continued every 8 h either with (group A) or without (group B) monitoring and dose adjustments according to sulfamethoxazole levels in serum (target, 150 to 200 micrograms/ml) for a total of 21 days. Only 7 of 19 patients (83%). Patients who were treated for the full period and patients for whom co-trimoxazole was prematurely stopped had similar concentrations of sulfamethoxazole (157 +/- 52 versus 155 +/- 47 micrograms/ml) and trimethoprim (5.0 +/- 1.4 versus 5.6 +/- 1.0 microgram/ml). Concentrations of sulfamethoxazole and trimethoprim in group A (158 +/- 39 and 5.6 +/- 1.8 micrograms/ml, respectively) did not differ from those in group B (153 +/- 57 and 5.1 +/- 1.6 micrograms/ml, respectively), and the average daily maintenance doses for groups A (75.4 mg/kg plus 15.1 mg/kg) and B (76.4 mg/kg plus 15.3 mg/kg) were nearly identical. Although the average sulfamethoxazole concentrations were maintained within the target zone in the monitoring group (day 5, 160 +/- 44 micrograms/ml; day 10, 160 +/- 41 micrograms/ml; day 15, 168 +/- micrograms/ml; and day 21, 157 +/- 95 micrograms/ml), only 28% of the individual sulfamethoxazole levels were within the target range of 150 to 200 micrograms/ml after the dose adjustments (32% in group B without intervention). Response rates were similar in both groups. Complete response or improvement was observed in 18 of 19 (group A) and 19 of 21 (group B) patients. The method used for monitoring sulfamethoxazole levels with subsequent dose adjustment did not allow us to reliably achieve the target concentrations and did not significantly alter the incidence of side effects or the efficacy of the therapy.

Full Text

The Full Text of this article is available as a PDF (207.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Blaser J., Joos B., Opravil M., Lüthy R. Variability of serum concentrations of trimethoprim and sulfamethoxazole during high dose therapy. Infection. 1993 Jul-Aug;21(4):206–209. doi: 10.1007/BF01728888. [DOI] [PubMed] [Google Scholar]
  2. Bowden F. J., Harman P. J., Lucas C. R. Serum trimethoprim and sulphamethoxazole levels in AIDS. Lancet. 1986 Apr 12;1(8485):853–853. doi: 10.1016/s0140-6736(86)90958-x. [DOI] [PubMed] [Google Scholar]
  3. Bozkurt A., Basci N. E., Isimer A., Tuncer M., Erdal R., Kayaalp S. O. Sulphamethoxazole acetylation in fast and slow acetylators. Int J Clin Pharmacol Ther Toxicol. 1990 Apr;28(4):164–166. [PubMed] [Google Scholar]
  4. Carr A., Gross A. S., Hoskins J. M., Penny R., Cooper D. A. Acetylation phenotype and cutaneous hypersensitivity to trimethoprim-sulphamethoxazole in HIV-infected patients. AIDS. 1994 Mar;8(3):333–337. doi: 10.1097/00002030-199403000-00006. [DOI] [PubMed] [Google Scholar]
  5. Carr A., Swanson C., Penny R., Cooper D. A. Clinical and laboratory markers of hypersensitivity to trimethoprim-sulfamethoxazole in patients with Pneumocystis carinii pneumonia and AIDS. J Infect Dis. 1993 Jan;167(1):180–185. doi: 10.1093/infdis/167.1.180. [DOI] [PubMed] [Google Scholar]
  6. Chin T. W., Vandenbroucke A., Fong I. W. Pharmacokinetics of trimethoprim-sulfamethoxazole in critically ill and non-critically ill AIDS patients. Antimicrob Agents Chemother. 1995 Jan;39(1):28–33. doi: 10.1128/aac.39.1.28. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Hughes W., Leoung G., Kramer F., Bozzette S. A., Safrin S., Frame P., Clumeck N., Masur H., Lancaster D., Chan C. Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS. N Engl J Med. 1993 May 27;328(21):1521–1527. doi: 10.1056/NEJM199305273282103. [DOI] [PubMed] [Google Scholar]
  8. Jaffe H. S., Abrams D. I., Ammann A. J., Lewis B. J., Golden J. A. Complications of co-trimoxazole in treatment of AIDS-associated Pneumocystis carinii pneumonia in homosexual men. Lancet. 1983 Nov 12;2(8359):1109–1111. doi: 10.1016/s0140-6736(83)90627-x. [DOI] [PubMed] [Google Scholar]
  9. Koopmans P. P., van der Ven A. J., Vree T. B., van der Meer J. W. Pathogenesis of hypersensitivity reactions to drugs in patients with HIV infection: allergic or toxic? AIDS. 1995 Mar;9(3):217–222. [PubMed] [Google Scholar]
  10. Opravil M., Hirschel B., Lazzarin A., Heald A., Pechère M., Rüttimann S., Iten A., von Overbeck J., Oertle D., Praz G. Once-weekly administration of dapsone/pyrimethamine vs. aerosolized pentamidine as combined prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus-infected patients. Clin Infect Dis. 1995 Mar;20(3):531–541. doi: 10.1093/clinids/20.3.531. [DOI] [PubMed] [Google Scholar]
  11. Rieder M. J., Krause R., Bird I. A., Dekaban G. A. Toxicity of sulfonamide-reactive metabolites in HIV-infected, HTLV-infected, and noninfected cells. J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Feb 1;8(2):134–140. [PubMed] [Google Scholar]
  12. Rieder M. J., Shear N. H., Kanee A., Tang B. K., Spielberg S. P. Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions. Clin Pharmacol Ther. 1991 Jan;49(1):13–17. doi: 10.1038/clpt.1991.3. [DOI] [PubMed] [Google Scholar]
  13. Rieder M. J., Uetrecht J., Shear N. H., Cannon M., Miller M., Spielberg S. P. Diagnosis of sulfonamide hypersensitivity reactions by in-vitro "rechallenge" with hydroxylamine metabolites. Ann Intern Med. 1989 Feb 15;110(4):286–289. doi: 10.7326/0003-4819-110-4-286. [DOI] [PubMed] [Google Scholar]
  14. Rieder M. J., Uetrecht J., Shear N. H., Spielberg S. P. Synthesis and in vitro toxicity of hydroxylamine metabolites of sulfonamides. J Pharmacol Exp Ther. 1988 Feb;244(2):724–728. [PubMed] [Google Scholar]
  15. Sattler F. R., Cowan R., Nielsen D. M., Ruskin J. Trimethoprim-sulfamethoxazole compared with pentamidine for treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective, noncrossover study. Ann Intern Med. 1988 Aug 15;109(4):280–287. doi: 10.7326/0003-4819-109-4-280. [DOI] [PubMed] [Google Scholar]
  16. Vöhringer H. F., Arastéh K. Pharmacokinetic optimisation in the treatment of Pneumocystis carinii pneumonia. Clin Pharmacokinet. 1993 May;24(5):388–412. doi: 10.2165/00003088-199324050-00004. [DOI] [PubMed] [Google Scholar]
  17. Wharton J. M., Coleman D. L., Wofsy C. B., Luce J. M., Blumenfeld W., Hadley W. K., Ingram-Drake L., Volberding P. A., Hopewell P. C. Trimethoprim-sulfamethoxazole or pentamidine for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective randomized trial. Ann Intern Med. 1986 Jul;105(1):37–44. doi: 10.7326/0003-4819-105-1-37. [DOI] [PubMed] [Google Scholar]
  18. van der Ven A. J., Koopmans P. P., Vree T. B., van der Meer J. W. Adverse reactions to co-trimoxazole in HIV infection. Lancet. 1991 Aug 17;338(8764):431–433. doi: 10.1016/0140-6736(91)91046-w. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES